KG&L Capital Management LLC Takes $89,000 Position in Actuate Therapeutics (NASDAQ:ACTU)

KG&L Capital Management LLC purchased a new position in shares of Actuate Therapeutics (NASDAQ:ACTU) in the third quarter, HoldingsChannel.com reports. The fund purchased 12,000 shares of the company’s stock, valued at approximately $89,000.

Actuate Therapeutics Stock Performance

Actuate Therapeutics stock opened at $8.77 on Tuesday. The business’s 50 day moving average price is $7.71. Actuate Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $10.16.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings data on Tuesday, September 24th. The company reported ($4.20) EPS for the quarter.

Insider Activity at Actuate Therapeutics

In other news, major shareholder Leslie W. Kreis sold 24,999 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total value of $224,991.00. Following the completion of the sale, the insider now owns 131,248 shares of the company’s stock, valued at approximately $1,181,232. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Todd S. Thomson sold 18,750 shares of Actuate Therapeutics stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $8.00, for a total transaction of $150,000.00. Following the completion of the sale, the insider now owns 1,184,795 shares of the company’s stock, valued at approximately $9,478,360. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Leslie W. Kreis sold 24,999 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total transaction of $224,991.00. Following the transaction, the insider now directly owns 131,248 shares in the company, valued at $1,181,232. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.